Background: Transcatheter mitral valve-in-valve (TMVIV) and valve-in-ring (TMVIR)
| Statistical analysis
Continuous variables are described as means and standard deviations for normally distributed data, or medians and interquartile ranges for non-normally distributed data. Differences between continuous variables were analyzed using a t-test. Categorical variables are described with absolute and relative frequencies. Differences between categorical variables were evaluated using the chi-square test or Fisher's exact test. Survival curves were estimated by the KaplanMeier method. A P-value <0.05 was considered statistically significant. this meta-analysis are summarized in Table 1 .
| RESULTS

| Baseline characteristics of patients
| Procedure
Transapical (TA) access was performed in 127 (55.2%) cases, and transseptal (TS) access (via a transfemoral or transjugular venous route) was performed in 91 (37.7%) patients. In addition to TA and TS access, a direct transatrial access using a sheath placed directly into the left atrium via a right anterior thoracotomy was also used in two patients. 67, 101 The "TA + TS" access was utilized for the Melody Inc, Santa Rosa, CA). postprocedure. The mean transmitral gradient decreased after both procedures (P < 0.001), and the NYHA function improved significantly (Table 3 ). The cumulative events at 30 days and 6 months postoperatively are shown in Table 4 . Three and nine additional deaths (Table 5) , no significant differences were observed between the MR and MS groups, but MS patients in the TMVIR group had a higher mean transmitral gradient (P = 0.002). Different mitral failure modes (MR and MS) did not affect the patient's overall survival in both the TMVIV and TMVIR procedures (P = 0.347 and 0.958, respectively) ( Figure 2 ).
| Clinical outcomes
| Comparison of different access routes
Patients who underwent the TMVIV procedure via TA access had a higher incidence of concomitant aortic or tricuspid valve dysfunction Patients who underwent the TMVIR procedure via TA access had a higher mean logistic EuroSCORE, and MR was more severe in patients who underwent the procedure via TS access (93.3% vs 56.0%, P = 0.001). No significant differences were observed in clinical outcomes at discharge (Table 6 ). Different access routes (TA and TS)
did not affect the patient's overall survival in both the TMVIV and TMVIR procedures (P = 0.450 and 0.361, respectively) ( Figure 3 ).
| Percentage of oversized valves
We collected manufacturer inner diameter (ID) measurements for MOSAIC and HANCOCK bioprostheses and the size of the ES valve (Table 7) 9 .6% (n = 38, more than 376 days), 63 and 42.4% (n = 24, 3 years). 108 Additionally, comparisons with surgical mitral valve replacement were unavailable, and only one ongoing controlled trial (NCT03242642) is currently being conducted.
Wunderlich et al 96 found that the transcatheter valve could be adequately deployed within failed bioprostheses, but the failed annuloplasty ring was too oval-shaped to adapt to the configuration of the implanted valve and would be more likely to develop MR.
Notably, the TMVIV procedure was associated with a higher technical success rate (97.1%) than the TMVIR procedure (84.9%, P = 0.001), and a lower postprocedural MR rate (P = 0.039) was also observed for the TMVIV procedure. This result was similar to that of Yoon et al 107 (248 patients from a transcatheter mitral valve replacement multicenter registry). Of the five patients (2.9%) experiencing TMVIV failures, two were due to operative error, and three others were due to prosthesis migration: two into the left atrium and one into the left ventricle. Regarding the TMVIR procedure, technical issues caused all the failures (n = 11, 15.1%). Three of the 11 failures were due to partial ring dehiscence following prosthesis deployment, and one failure was related to incomplete ring expansion. Anatomical differences also account for the differences in the technical success rate and post-procedure MR rate between the TMVIV and TMVIR procedures.
The native mitral valve leaflets in failed rings may disrupt the valve fixation and alter motion of the transcatheter mitral leaflets and the failed ring may be deformed during deployment.
| MR versus MS failure mode
Different mitral failure modes are associated with specific anatomic and hemodynamic characteristics. Performing a retrograde implantation in the presence of MS is more difficult than performing this procedure in the presence of MR due to the difficulty in crossing the bioprostheses with the wire and implanting the transcatheter valves.
Some issues arise when the TA access route is chosen. Pagnotta et al 33 reported that they changed to the TS access route because they were unable to cross the degenerated mitral valve bioprostheses after multiple attempts. However, no clinical data exist to address these issues at present, and almost all on-going trials are only designed for MR patients. In our analysis, both patients with MR or MS achieved a high technical success rate and good clinical outcomes, and no significant differences were observed in the early clinical outcomes for access routes, but no significant differences were found.
| TA versus TS access
The first transcatheter mitral valve implantation in humans was performed via TS access. 3 In 2013, all TMVIV procedures were successfully performed via a TA approach. 63 The TA route was used for most procedures. The TA access has the following advantages: (1) direct and co-axial access; (2) shorter distance; and (3) better control during deployment. The TA is also the first choice for patients with peripheral vascular disease. The TS route also has several advantages, including being less invasive and can be done under local anesthesia.
However, the TS access route can cause an iatrogenic atrial septal defect (ASD), and some patients (16.5%) required an ASD occluder. A study by Frerker et al showed no significant differences in clinical outcomes, especially bleeding and vascular complications between the 
| Analysis of valve migration
Valve migration was the main (37.5%) cause of technical failure for these procedures. Eight patients developed valve migration into the LA either instantly in the cath lab or delayed/after exiting from the catheterization laboratory. In the TMVIV procedure, two patients (1.2%) developed valve migration to the LA after deployment, and five patients (8.3%) developed delayed migration. We found two cases (2.7%) of instant migration to the LA, one case (1.4%) of migration to the LV and no delayed migrations in the TMVIR procedure. Although no significant differences were observed between the TMVIV and TMVIR procedures for delayed migration (P = 0.452), more cases of migration were associated with the TMVIR procedure.
| Optimal valve positions
The optimal positions for valves for both the MIVIV and TMVIR procedures have not been determined. The SAPIEN/SAPIEN XT device should be implanted in the mitral position with 10-20% of the device located atrially. 55 In our analysis, four patients underwent successful TMVIV surgery using the SAPIEN/SAPIEN XT valve, and the positions were as follows: 1/3 of the valves were above the annular level and 2/3 beneath this level 34 ; 30% of the new prostheses were on the atrial side, and the SAPIEN was 10% higher on the atrial end 27 with 10% bias toward the atrial side. 40 The 1-year follow-up results were reported in only one of the four cases. At the 6-month follow-up, one of the three pericardial leaflets was stuck in the closed position; however, the patient was in excellent clinical condition. Fluoroscopy showed an "hour-glass"
shape of the SAPIEN XT valve due to a final positioning that favored the atrial side (30% to 35% on the atrial side). 52 Unlike the TMVIV procedure, no consensus exists regarding the optimal position for the TMVIR procedure. A total of nine articles reported variable positions.
The three different positions of the ES valve are as follows: (1) less atrium more ventricle: 1/3 in the atrium and 2/3 in the ventricle 75, 101, 104 or 40% in the atrium and 60% in the ventricle 90, 105 ; (2) 98 and 40% in the atrium and 60% in the ventricle. 100 All patients had successful TMVIR surgery and good clinical outcomes before discharge, and no migrations occurred. The position of the valve in the TMVIR procedure may be not as important as that in the TMVIV procedure. We found that the valve could be deployed more conically, and the position has little influence on valve expansion.
| Sizing considerations
Currently, the ID of the valve set by the manufacturers is the most important criteria for transcatheter valve sizing for the TMVIV and TMVIR procedure. In a series by Cheung et al, 63 the pre-existing prosthesis was oversized by a minimum of 10% according to the manufacturer's ID. However, Seiffert et al 70 suggested that oversizing should be limited in cases with a rigid xenograft stent because it may result in uneven stent expansion and leaflet distortion. In our study, the | 515 mean extent of oversizing in MR patients was greater than that in MS patients, but both mean proportions were less than 10%, with no significant difference between groups (P = 0.141). Due to a lack of data regarding migration, we could not determine whether migration occurred more frequently in patients with a larger mean extent of oversizing.
| Limitations
This is an observational study and all patients' data were obtained from published articles collected during a comprehensive and systematic search. Only a few articles reported long-term follow-up data;
therefore, evaluation of long-term outcomes was not possible. All studies included in this study lacked control groups. 
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